ANI Pharmaceuticals, Inc. $ANIP Stock Position Decreased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd trimmed its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 79.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,423 shares of the specialty pharmaceutical company’s stock after selling 35,983 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in ANI Pharmaceuticals were worth $725,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Arrowstreet Capital Limited Partnership acquired a new position in ANI Pharmaceuticals in the third quarter worth approximately $32,992,000. Balyasny Asset Management L.P. raised its position in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after acquiring an additional 276,233 shares in the last quarter. Divisadero Street Capital Management LP acquired a new stake in ANI Pharmaceuticals in the third quarter valued at approximately $21,454,000. Rubric Capital Management LP lifted its stake in ANI Pharmaceuticals by 354.7% in the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after acquiring an additional 200,998 shares during the last quarter. Finally, UBS Group AG grew its position in ANI Pharmaceuticals by 45.8% in the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after acquiring an additional 185,172 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 2,772 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the completion of the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at $6,256,332. The trade was a 3.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 55,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $77.57, for a total transaction of $4,266,350.00. Following the sale, the chief executive officer owned 349,889 shares of the company’s stock, valued at $27,140,889.73. This trade represents a 13.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 84,679 shares of company stock worth $6,681,676 in the last ninety days. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Price Performance

ANIP opened at $82.07 on Monday. The business has a 50 day moving average price of $81.58 and a 200 day moving average price of $79.50. ANI Pharmaceuticals, Inc. has a twelve month low of $62.60 and a twelve month high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The firm has a market cap of $1.87 billion, a P/E ratio of 20.78 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same quarter in the prior year, the business earned $1.70 earnings per share. The company’s revenue was up 20.5% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts forecast that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Guggenheim reaffirmed a “buy” rating and issued a $124.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, June 23rd. Finally, Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.